| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
Euphol targets monoacylglycerol lipase (MAGL), an enzyme involved in the endocannabinoid system. It inhibits MAGL activity via a reversible mechanism. Additionally, Euphol modulates the endocannabinoid system peripherally to block the development of inflammatory pain. It also inhibits NF-κB activation and reduces pro-inflammatory cytokine production.
|
|---|---|
| ln Vitro |
T47D cell proliferation was markedly decreased by euphorbiol (0.01-0.3 mM; 24-72 hours); the IC50 values of euphorbiol treatment for 24, 48, and 72 hours were, respectively, 0.26, 0.22, and 0.13 mM [2]. By controlling the expression of proteins linked to the cell cycle, euphol (0.03 mM; 48 or 72 hours) induces cell cycle arrest [2].
In vitro, Euphol inhibits monoacylglycerol lipase (MAGL) activity with an IC50 of 315 nM through a reversible mechanism. It suppresses tumor cell growth by inducing apoptosis and cell cycle arrest in various cancer cell lines. Euphol also reduces the production of pro-inflammatory cytokines in cultured cells. |
| ln Vivo |
In vivo, Euphol produces antinociceptive effects in inflammatory and neuropathic pain models through the involvement of the cannabinoid system. Peripheral MAGL inhibition by Euphol modulates the endocannabinoid system, thereby preventing the development of inflammatory pain. Its anti-inflammatory and analgesic activities have been demonstrated in animal models of pain.
|
| Enzyme Assay |
The in vitro enzyme activity assay for Euphol typically involves measuring its inhibitory effect on monoacylglycerol lipase (MAGL) activity. Recombinant MAGL enzyme is incubated with varying concentrations of Euphol and a fluorogenic substrate. The inhibition constant (IC50) is determined by monitoring the decrease in enzymatic activity, with Euphol showing a reversible mechanism of inhibition with an IC50 of 315 nM.
|
| Cell Assay |
Cell proliferation assay[2]
Cell Types: T47D Cell Tested Concentrations: 0.01, 0.03, 0.1 and 0.3 mM Incubation Duration: 24, 48 and 72 hrs (hours) Experimental Results: diminished percentage of viable cells. Western Blot Analysis [2] Cell Types: T47D cell Tested Concentrations: 0.03 mM Incubation Duration: 48 and 72 hrs (hours) Experimental Results: The expression of p21 and p27 increased, and the expression of cyclin A, B1 and D diminished. In vitro cellular assays for Euphol involve treating cultured cancer cell lines or immune cells with varying concentrations of the compound. Cell viability is assessed using MTT or similar assays to evaluate antiproliferative effects. Cytokine levels in the culture medium are measured by ELISA to assess anti-inflammatory activity. Apoptosis is detected by flow cytometry using Annexin V staining. |
| Animal Protocol |
In vivo animal experiments for Euphol typically use rodent models of inflammatory and neuropathic pain. Euphol is administered via appropriate routes (e.g., oral, intraperitoneal) at various doses. Pain responses are evaluated using standard behavioral tests such as the formalin test, hot plate test, or von Frey filament test. The antinociceptive effect is assessed, and the involvement of the cannabinoid system is investigated using specific antagonists.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Euphol have not been extensively characterized in publicly available literature. As a tetracyclic triterpene with high lipophilicity (logP estimated ~7-8), Euphol is expected to have low oral bioavailability and extensive plasma protein binding. It is likely metabolized by cytochrome P450 enzymes in the liver and excreted via biliary route. The compound's high molecular weight (426.72) and lipophilic nature may limit its distribution to the central nervous system.
|
| Toxicity/Toxicokinetics |
Toxicological (toxicology) data for Euphol are limited in publicly available sources. As a natural product with a long history of use in traditional medicine, Euphol is generally considered to have a moderate safety profile. However, systematic toxicology studies including acute toxicity, repeated-dose toxicity, genotoxicity, and reproductive toxicity have not been well documented in the scientific literature. Standard safety pharmacology studies would be required for full toxicological characterization.
|
| References |
|
| Additional Infomation |
Euphol is a triterpenoid compound. It has been reported to exist in tea plants, Euphorbia species, and other organisms with relevant data.
Euphol (CAS#: 514-47-6) is a natural tetracyclic triterpene alcohol primarily derived from Euphorbia species latex. Its mechanism of action involves inhibition of MAGL, which modulates the endocannabinoid system to produce antinociceptive effects. Euphol also exhibits anti-inflammatory effects through NF-κB inhibition and reduction of pro-inflammatory cytokines. The compound is not approved for clinical use and remains an investigational tool for studying pain, inflammation, and cancer. |
| Molecular Formula |
C30H50O
|
|---|---|
| Molecular Weight |
426.72
|
| Exact Mass |
426.386
|
| CAS # |
514-47-6
|
| PubChem CID |
441678
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
498.9±44.0 °C at 760 mmHg
|
| Melting Point |
116-117ºC
|
| Flash Point |
221.1±20.7 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.530
|
| LogP |
11
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
31
|
| Complexity |
767
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H](CCC=C(C)C)[C@@H]1CC[C@]2([C@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C
|
| InChi Key |
CAHGCLMLTWQZNJ-WZLOIPHISA-N
|
| InChi Code |
InChI=1S/C30H50O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h10,21-22,25-26,31H,9,11-19H2,1-8H3/t21-,22+,25+,26+,28-,29+,30-/m1/s1
|
| Chemical Name |
(3S,5R,10R,13R,14S,17R)-4,4,10,13,14-pentamethyl-17-((R)-6-methylhept-5-en-2-yl)-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| Synonyms |
NSC-36571 NSC 36571 Euphol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~58.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.86 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3435 mL | 11.7173 mL | 23.4346 mL | |
| 5 mM | 0.4687 mL | 2.3435 mL | 4.6869 mL | |
| 10 mM | 0.2343 mL | 1.1717 mL | 2.3435 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
